RESPECT ESUS: Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acetylsalicylic acid (100 mg oral q.d.) in patients with Embolic Stroke of undetermined Source
22.01.2016
There is uncertainty over the optimal stroke prevention treatment for patients with ESUS. The current treatment recommendations of ASA alone, sometimes given with clopidogrel or ticlopidine (P08-06684, P08-08481) are based on limited data.
There is s...
Klinische Forschung -
22.01.2016 - 01.01.2018
Automatisch geschlossen
Projektleitung: Kägi Georg
Mitarbeiter/innen: Vehoff Jochen, Mbialeu Suzie
Weiter
